This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Rosenberg B, Van Camp L, Grimley EB, Thomson AJ. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem 1967; 242: 1347-52. PMID: 5337590RosenbergBVanCamp LGrimleyEBThomsonAJThe inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexesJ Biol Chem1967242134752PMID: 533759010.1016/S0021-9258(18)96186-7Search in Google Scholar
Rosenberg B. Van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1969; 222: 385-6. PMID: 5782119RosenbergBVanCamp LTroskoJEMansourVHPlatinum compounds: a new class of potent antitumor agentsNature19692223856PMID: 578211910.1038/222385a05782119Search in Google Scholar
Peyrone M. Über die einwirkungdes ammoniaks auf platichlorür. Annalen der chemie und pharmacie 1844; 51: 1-29. 10.1002/jlac.18440510102PeyroneMÜber die einwirkungdes ammoniaks auf platichlorürAnnalen der chemie und pharmacie18445112910.1002/jlac.18440510102Open DOISearch in Google Scholar
Rosenberg B. Some biological effects of platinum compounds. New agents for the control of tumours. Platinum Met Rev 1971; 15: 42-51.RosenbergBSome biological effects of platinum compounds. New agents for the control of tumoursPlatinum Met Rev1971154251Search in Google Scholar
Apps MG, Choi EHY, Wheate NJ. The state-of-play and future of platinum drugs. Endocr Relat Cancer 2015; 22: R219-33. 10.1530/ERC-15-0237AppsMGChoiEHYWheateNJThe state-of-play and future of platinum drugsEndocr Relat Cancer201522R2193310.1530/ERC-15-023726113607Open DOISearch in Google Scholar
Dabrowiak JC. Metals in medicine 2nd edition. John Wiley & Sons Ltd; 2017. p. 94-5.DabrowiakJCMetals in medicine2nd editionJohn Wiley & Sons Ltd201794510.1002/9781119191377Search in Google Scholar
Sooriyaarachchi M, Narendran A. Gailer J. Comparative hydrolysis and plasma protein binding of cisplatin and carboplatin in human plasma in vitro. Metallomics 2011; 3: 49-55. 10.1039/c0mt00058bSooriyaarachchiMNarendranAGailerJComparative hydrolysis and plasma protein binding of cisplatin and carboplatin in human plasma in vitroMetallomics20113495510.1039/c0mt00058b21135941Open DOISearch in Google Scholar
Handing KB, Shabalin IG, Kassaar O, Khazaipoul S, Blindauer CA, Stewart AJ, et al. Circulatory zinc transport is controlled by distinct interdomain sites on mammalian albumins. Chem Sci Chem 2016; 7: 6635-48. 10.1039/c6sc02267gHandingKBShabalinIGKassaarOKhazaipoulSBlindauerCAStewartAJCirculatory zinc transport is controlled by distinct interdomain sites on mammalian albuminsChem Sci Chem2016766354810.1039/c6sc02267g545052228567254Open DOISearch in Google Scholar
Hu W, Luo Q, Wu K, Li X, Wang F, Chen Y, et al. The anticancer drug cisplatin can crosslink the interdomain zinc site on human albumin. Chem Commun (Camb) 2011; 47: 6006-8. 10.1039/c1cc11627dHuWLuoQWuKLiXWangFChenYThe anticancer drug cisplatin can crosslink the interdomain zinc site on human albuminChem Commun (Camb)2011476006810.1039/c1cc11627d21526258Open DOISearch in Google Scholar
Martinčič A, Cemazar M, Serša G, Kovač V, Milačič R, Ščančar J. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection. Talanta 2013; 116: 141-8. 10.1016/j.talanta.2013.05.016MartinčičACemazarMSeršaGKovačVMilačičRŠčančarJA novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detectionTalanta2013116141810.1016/j.talanta.2013.05.01624148385Open DOISearch in Google Scholar
Eljack ND, Ma HY, Drucker J, Shen C, Hambley TW, New EJ, et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics 2014; 6: 2126-33. 10.1039/c4mt00238eEljackNDMaHYDruckerJShenCHambleyTWNewEJMechanisms of cell uptake and toxicity of the anticancer drug cisplatinMetallomics2014621263310.1039/c4mt00238e25306996Open DOISearch in Google Scholar
Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008; 48: 495-535. 10.1146/annurev.pharmtox.48.080907.180426HallMDOkabeMShenDWLiangXJGottesmanMMThe role of cellular accumulation in determining sensitivity to platinum-based chemotherapyAnnu Rev Pharmacol Toxicol20084849553510.1146/annurevpharmtox.48.080907.18042617937596Open DOISearch in Google Scholar
Eljack ND, Ma MH, Drucker J, Shen C, Hambley TW, New JE, et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics 2014; 6: 2126-33. 10.1039/c4mt00238eEljackNDMaMHDruckerJShenCHambleyTWNewJEMechanisms of cell uptake and toxicity of the anticancer drug cisplatinMetallomics2014621263310.1039/c4mt00238e25306996Open DOISearch in Google Scholar
Lasorsa A, Natile G, Rosato A, Tadini-Buoninsegni F, Arnesano F. Monitoring interactions inside cells by advanced spectroscopies: overview of copper transporters and cisplatin. Curr Med Chem 2018; 25: 462-77. 10.2174/0929867324666171110141311LasorsaANatileGRosatoATadini-BuoninsegniFArnesanoFMonitoring interactions inside cells by advanced spectroscopies: overview of copper transporters and cisplatinCurr Med Chem2018254627710.2174/092986732466617111014131129121854Open DOISearch in Google Scholar
Holzer AK, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 2006; 66: 10944-52. 10.1158/0008-5472.CAN-06-1710HolzerAKHowellSBThe internalization and degradation of human copper transporter 1 following cisplatin exposureCancer Res200666109445210.1158/0008-5472.CAN-06-171017108132Open DOISearch in Google Scholar
Ivy KD, Kaplan JH. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol 2013; 83: 1237-46. 10.1124/mol.113.085068IvyKDKaplanJHA re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cellsMol Pharmacol20138312374610.1124/mol.113.085068365710323543413Open DOISearch in Google Scholar
Arnesano F, Seintilla S, Natile G. Interaction between platinum complexes and a methionine motif found in copper transport proteins. Angew Chem Int Ed Engl 2007; 46: 9062-4. 10.1002/anie.200703271ArnesanoFSeintillaSNatileGInteraction between platinum complexes and a methionine motif found in copper transport proteinsAngew Chem Int Ed Engl2007469062410.1002/anie.20070327117886318Open DOISearch in Google Scholar
Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006; 319: 879-86. 10.1124/jpet.106.110346YonezawaAMasudaSYokooSKatsuraTInuiKCisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)J Pharmacol Exp Ther20063198798610.1124/jpet.106.11034616914559Open DOISearch in Google Scholar
Nieskens TTG, Peters JGP, Dabaghie D, Korte D, Jansen K, Van Asbeck AH, et al. Expression of organic anion transporter 1 or 3 in human kidney proximal tubule cells reduces cisplatin sensitivity. Drug Metab Dispos 2018; 46: 5929. 10.1124/dmd.117.079384NieskensTTGPetersJGPDabaghieDKorteDJansenKVanAsbeck AHExpression of organic anion transporter 1 or 3 in human kidney proximal tubule cells reduces cisplatin sensitivityDrug Metab Dispos201846592910.1124/dmd.117.07938429514829Open DOISearch in Google Scholar
Ciarimboli G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res 2014; 34: 547-50. PMID: 24403515.CiarimboliGMembrane transporters as mediators of cisplatin side-effectsAnticancer Res20143454750PMID: 2440351510.6064/2012/473829382046224278698Search in Google Scholar
Calandrini V, Arnesano F, Galliani A, Nguyen TH, Ippoliti E, Carloni P, et al. Platination of the copper transporter ATP7A involved in anticancer drug resistance. Dalton Trans 2014; 43: 12085-94. 10.1039/c4dt01339eCalandriniVArnesanoFGallianiANguyenTHIppolitiECarloniPPlatination of the copper transporter ATP7A involved in anticancer drug resistanceDalton Trans201443120859410.1039/c4dt01339e24983998Open DOISearch in Google Scholar
Aggarwal A, Bhatt M. Advances in treatment of Wilson disease. Tremor Other Hyperkinet Mov (NY) 2018; 8: 525. 10.7916/D841881DAggarwalABhattMAdvances in treatment of Wilson diseaseTremor Other Hyperkinet Mov (NY)2018852510.7916/D841881DOpen DOISearch in Google Scholar
Ferreira CR, Gahl WA. Disorders of metal metabolism. Transl Sci Rare Dis 2017; 2: 101-39. 10.3233/TRD-170015FerreiraCRGahlWADisorders of metal metabolismTransl Sci Rare Dis201721013910.3233/TRD-170015Open DOISearch in Google Scholar
Tadini-Buoninsegni F, Bartolommei G, Moncelli MR, Inesi G, Galliani A, Sinisi M, et al. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B. Angew Chem Int Ed Engl 2014; 53: 1297-301. 10.1002/anie.201307718Tadini-BuoninsegniFBartolommeiGMoncelliMRInesiGGallianiASinisiMTranslocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7BAngew Chem Int Ed Engl201453129730110.1002/anie.201307718Open DOISearch in Google Scholar
Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, Igarashi M, et al. Overexpression of metallothionein correlates with chemo resistance to cisplatin and prognosis in oesophageal cancer. Oncology 1997; 54: 342-7. 10.1159/000227714HishikawaYAbeSKinugasaSYoshimuraHMondenNIgarashiMOverexpression of metallothionein correlates with chemo resistance to cisplatin and prognosis in oesophageal cancerOncology199754342710.1159/000227714Open DOISearch in Google Scholar
Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukaemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993; 268: 20116-25. PMID: 8376370.IshikawaTAli-OsmanFGlutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukaemia cells. Molecular characterization of glutathione-platinum complex and its biological significanceJ Biol Chem19932682011625PMID: 837637010.1016/S0021-9258(20)80702-9Search in Google Scholar
Chen HH, Kuo MT. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010; pii: 430939. 10.1155/2010/430939ChenHHKuoMTRole of glutathione in the regulation of cisplatin resistance in cancer chemotherapyMet Based Drugs201043093910.1155/2010/430939294657920885916Open DOISearch in Google Scholar
Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC, et al. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacol Res 2016; 110: 89-95. 10.1016/j.phrs.2016.05.012SauzayCWhite-KoningMHennebelleIDelucheTDelmasCImbsDCInhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatinPharmacol Res2016110899510.1016/j.phrs.2016.05.01227178732Open DOISearch in Google Scholar
Sprowl JA, Ness RA, Sparreboom A. Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet 2013; 28: 19-27. PMID: 22986709SprowlJANessRASparreboomAPolymorphic transporters and platinum pharmacodynamicsDrug Metab Pharmacokinet2013281927PMID: 2298670910.2133/dmpk.DMPK-12-RV-073Search in Google Scholar
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009; 86: 396-402. 10.1038/clpt.2009.139FilipskiKKMathijssenRHMikkelsenTSSchinkelAHSparreboomAContribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicityClin Pharmacol Ther20098639640210.1038/clpt.2009.139274686619625999Open DOISearch in Google Scholar
Tzvetkov MV, Behrens G, O’Brien VP, Hohloch K, Brockmöller J, Benöhr P. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics 2011; 12: 1417-27. 10.2217/pgs.11.93TzvetkovMVBehrensGO’BrienVPHohlochKBrockmöllerJBenöhrPPharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphismsPharmacogenomics20111214172710.2217/pgs.11.9321902499Open DOISearch in Google Scholar
Hsu CM, Lin PM, Chang JG, Lin HC, Li SH, Lin SF, et al. Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment. Oncotarget 2017; 8: 74348-58. 10.18632/oncotarget.20637HsuCMLinPMChangJGLinHCLiSHLinSFUpregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatmentOncotarget20178743485810.18632/oncotarget.20637565034629088791Open DOISearch in Google Scholar
Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D, et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 2009; 9: 127-36. 10.1038/tpj.2008.19ChenYTeranishiKLiSYeeSWHesselsonSStrykeDGenetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport functionPharmacogenomics J200991273610.1038/tpj.2008.19294906219172157Open DOISearch in Google Scholar
Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111: 1843-50. 10.1289/ehp.6632AuWWSalamaSASierra-TorresCHFunctional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assaysEnviron Health Perspect200311118435010.1289/ehp.6632124174714630517Open DOISearch in Google Scholar
Osawa K. Gene polymorphisms and chemotherapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2009; 12: 837-40. 10.3779/j.issn.1009-3419.2009.08.01OsawaKGene polymorphisms and chemotherapy in non-small cell lung cancerZhongguo Fei Ai Za Zhi2009128374010.3779/jissn.1009-3419.2009.08.0120719167Open DOISearch in Google Scholar
de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M. Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17(4): 668-75. 10.1093/annonc/mdj135de lasPeñas RSanchez-RoncoMAlberolaVTaronMCampsCGarcia-CarboneroRPolymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patientsAnn Oncol20061746687510.1093/annonc/mdj13516407418Open DOISearch in Google Scholar
Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 2007; 107(1 Suppl 1): S223-9. 10.1016/j.ygyno.2007.07.024SaldivarJSLuKHLiangDGuJHuangMVlastosATMoving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patientsGynecol Oncol20071071 Suppl 1S223910.1016/j.ygyno.2007.07.02417825393Open DOISearch in Google Scholar
Goričar K, Kovač V, Jazbec J, Zakotnik B, Lamovec J, Dolžan V. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma. Cancer Epidemiol 2015; 39: 182-8. 10.1016/j.canep.2014.12.009GoričarKKovačVJazbecJZakotnikBLamovecJDolžanVGenetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcomaCancer Epidemiol201539182810.1016/j.canep.2014.12.00925592234Open DOISearch in Google Scholar
Deng JH, Deng J, Shi DH, Ouyang XN, P.-G. Niu PG. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced nonsmall cell lung cancer patients. Clin Transl Oncol 2015; 17: 720-6. 10.1007/s12094-015-1299-6DengJHDengJShiDHOuyangXNP.-G. NiuPGClinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced nonsmall cell lung cancer patientsClin Transl Oncol201517720610.1007/s12094-015-1299-626033426Open DOISearch in Google Scholar
Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumours. Am J Pathol 1996; 148: 877-87. PMID: 8774142.IzquierdoMASchefferGLFlensMJGiacconeGBroxtermanHJMeijerCJBroad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumoursAm J Pathol199614887787PMID: 8774142Search in Google Scholar
Sedláková I, Laco J, Caltová K, Červinka M, Tošner J, Řezáč A, et al. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer. Int J Gynecol Cancer 2015; 25(2): 236-43. 10.1097/IGC.0000000000000354SedlákováILacoJCaltováKČervinkaMTošnerJŘezáčAClinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancerInt J Gynecol Cancer20152522364310.1097/IGC.000000000000035425594141Open DOISearch in Google Scholar
Zhao YN, He DN, Wang YD, Li JJ, Ha MW. Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer. Oncol Lett 2016; 11(4): 2925-33. 10.3892/ol.2016.4311ZhaoYNHeDNWangYDLiJJHaMWAssociation of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancerOncol Lett201611429253310.3892/ol.2016.4311481254527073578Open DOISearch in Google Scholar
Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Wasif Saif M. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Metal-Based Drugs 2010; 2010: 1-11. 10.1155/2010/207084MakriliaNSyrigouEKaklamanosIManolopoulosLWasifSaif MHypersensitivity reactions associated with platinum antineoplastic agents: a systematic reviewMetal-Based Drugs2010201011110.1155/2010/207084294565420886011Open DOISearch in Google Scholar
Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, et al. Carboplatin hypersensitivity reaction in paediatric patients with low-grade glioma: a Canadian paediatric brain tumour consortium experience. Cancer 2008; 112: 892-9. 10.1002/cncr.23249Lafay-CousinLSungLCarretASHukinJWilsonBJohnstonDLCarboplatin hypersensitivity reaction in paediatric patients with low-grade glioma: a Canadian paediatric brain tumour consortium experienceCancer2008112892910.1002/cncr.2324918098210Open DOISearch in Google Scholar
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM Jr, Michelin DP, et al. Single agent carboplatin versus carboplatin plus PEGylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 2010; 116: 323-5. 10.1016/j.ygyno.2009.11.026MarkmanMMoonJWilczynskiSLopezAMRowlandKM JrMichelinDPSingle agent carboplatin versus carboplatin plus PEGylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trialGynecol Oncol2010116323510.1016/j.ygyno.2009.11.026283616820044128Open DOISearch in Google Scholar
van Meerten E, Franckena M, Wiemer E, van Doorn L, Kraan J, Westermann A, et al. Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area. Oncologist 2015; 20: 241-2. 10.1634/theoncologist.2014-0365vanMeerten EFranckenaMWiemerEvanDoorn LKraanJWestermannAPhase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated areaOncologist201520241210.1634/theoncologist.2014-0365435080025660155Open DOISearch in Google Scholar
Landon CD. Enhancing cisplatin delivery and anti-tumour efficacy using hyperthermia. [Dissertation]. Durcham: Duke University; 2013.LandonCDEnhancing cisplatin delivery and anti-tumour efficacy using hyperthermia[Dissertation]. DurchamDuke University2013Search in Google Scholar
Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 3144-53. 10.1056/NEJM199904153401502RosePGBundyBNWatkinsEBThigpenJTDeppeGMaimanMAConcurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancerN Engl J Med199934031445310.1056/NEJM19990415340150210202165Open DOISearch in Google Scholar
Biston MC, Joubert A, Adam JF, Elleaume H, Bohic S, Charvet AM, et al. Cure of Fisher rats bearing radio resistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-rays. Cancer Res 2004; 64: 2317-23. 10.1158/0008-5472.CAN-03-3600BistonMCJoubertAAdamJFElleaumeHBohicSCharvetAMCure of Fisher rats bearing radio resistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-raysCancer Res20046423172310.1158/0008-5472.CAN-03-3600Open DOISearch in Google Scholar
Coluccia D, Figueiredo CA, Wu MY, Riemenschneider AN, Diaz R, Luck A, et al. Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound. Nanomedicine 2018; 14: 1137-48. 10.1016/j.nano.2018.01.021ColucciaDFigueiredoCAWuMYRiemenschneiderANDiazRLuckAEnhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasoundNanomedicine20181411374810.1016/jnano.2018.01.02129471172Open DOISearch in Google Scholar
Schumann C, Chan S, Millar JA, Bortnyak Y, Carey K, Fedchyk A, et al. Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. Nanomedicine 2018; 14: 1395-405. 10.1016/j.nano.2018.03.005SchumannCChanSMillarJABortnyakYCareyKFedchykAIntraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatinNanomedicine201814139540510.1016/j.nano.2018.03.005617410329635082Open DOISearch in Google Scholar
Setua S, Ouberai M, Piccirillo SG, Watts C, Welland M. Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma. Nanoscale 2014; 6: 10865-73. 10.1039/c4nr03693jSetuaSOuberaiMPiccirilloSGWattsCWellandMCisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastomaNanoscale20146108657310.1039/c4nr03693j25117686Open DOISearch in Google Scholar
Shahin SA, Wang R, Simargi SI, Glackin CA. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumour burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 2017; 13: 965-76. 10.1016/j.nano.2018.04.00ShahinSAWangRSimargiSIGlackinCAHyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumour burden and enhances sensitivity to cisplatin in ovarian cancerNanomedicine2017139657610.1016/j.nano.2018.04.00Open DOISearch in Google Scholar
Joybari AY, Sarbaz S, Azadeh P, Mirafsharieh SA, Rahbari A, Farasatinasab M, et al. Oxaliplatin-induced renal tubular vacuolization. Ann Pharmacother 2014; 4: 796-800. 10.1177/1060028014526160JoybariAYSarbazSAzadehPMirafshariehSARahbariAFarasatinasabMOxaliplatin-induced renal tubular vacuolizationAnn Pharmacother2014479680010.1177/106002801452616024615628Open DOISearch in Google Scholar
Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, et al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009; 101: 37-47. 10.1093/jnci/djn418HellbergVWallinIErikssonSHernlundEJerremalmEBerndtssonMCisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicityJ Natl Cancer Inst2009101374710.1093/jnci/djn418263929519116379Open DOISearch in Google Scholar
Hosnedlova B, Kepinska M, Skalickova S, Fernandez C, Ruttkay-Nedecky B, Peng Q, et al. Nano-selenium and its nanomedicine applications: a critical review. Int J Nanomedicine 2018; 13: 2107-28. 10.2147/IJN.S157541HosnedlovaBKepinskaMSkalickovaSFernandezCRuttkay-NedeckyBPengQNano-selenium and its nanomedicine applications: a critical reviewInt J Nanomedicine20181321072810.2147/IJN.S157541590113329692609Open DOISearch in Google Scholar
Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005; 25: 3031-40. PMID: 16080562BoulikasTStathopoulosGPVolakakisNVougioukaMSystemic Lipoplatin infusion results in preferential tumor uptake in human studiesAnticancer Res200525303140PMID: 16080562Search in Google Scholar
Serinan E, Altun Z, Aktaş S, Çeçen E, Olgun N. Comparison of cisplatin with lipoplatin in terms of ototoxicity. J Int Adv Otol 2018; 14: 211-5. 10.5152/iao.2018.4097SerinanEAltunZAktaşSÇeçenEOlgunNComparison of cisplatin with lipoplatin in terms of ototoxicityJ Int Adv Otol201814211510.5152/iao.2018.4097635445429460824Open DOISearch in Google Scholar
Serša G, Čemažar M, Miklavčič D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 1995; 55: 3450-5. PMID: 7614485SeršaGČemažarMMiklavčičDAntitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in miceCancer Res19955534505PMID: 7614485Search in Google Scholar
Serša G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: Clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863-7. PMID: 107417SeršaGStabucBCemazarMMiklavcicDRudolfZElectrochemotherapy with cisplatin: Clinical experience in malignant melanoma patientsClin Cancer Res200068637PMID: 107417Search in Google Scholar
Gehl J, Sersa G, Wichmann Matthiessen L, Muir T, Soden D, Occhini A, et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 2018, 57: 874-882. 10.1080/0284186X.2018.1454602GehlJSersaGWichmannMatthiessen LMuirTSodenDOcchiniAUpdated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastasesActa Oncol20185787488210.1080/0284186X.2018.145460229577784Open DOISearch in Google Scholar
Kranjc S, Cemazar M, Sersa G, Scancar J, Grabner S. In vitro and in vivo evaluation of electrochemotherapy with trans-platinum analogue trans-[PtCl2(3-Hmpy)2]. Radiol Oncol 2017; 51: 295-306. 10.1515/raon-2017-0034KranjcSCemazarMSersaGScancarJGrabnerSIn vitro and in vivo evaluation of electrochemotherapy with trans-platinum analogue trans-[PtCl2(3-Hmpy)2]Radiol Oncol20175129530610.1515/raon-2017-0034561199428959166Open DOISearch in Google Scholar
Grabner S, Modec B, Bukovec N, Bukovec P, Čemažar M, Kranjc S, et al. Cytotoxic trans-platinum(II) complex with 3-hydroxymethylpyridine: Synthesis, X-ray structure and biological activity evaluation. J Inorg Biochem 2016; 161: 40-51. 10.1016/j.jinorgbio.2016.04.031GrabnerSModecBBukovecNBukovecPČemažarMKranjcSCytotoxic trans-platinum(II) complex with 3-hydroxymethylpyridine: Synthesis, X-ray structure and biological activity evaluationJ Inorg Biochem2016161405110.1016/j.jinorgbio.2016.04.03127189143Open DOISearch in Google Scholar
Sancho-Martínez SM, Prieto-García L, Prieto M, López-Novoa JM, López-Hernández FJ. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther 2012; 136: 35-55. 10.1016/j.pharmthera.2012.07.003Sancho-MartínezSMPrieto-GarcíaLPrietoMLópez-NovoaJMLópez-HernándezFJSubcellular targets of cisplatin cytotoxicity: an integrated viewPharmacol Ther2012136355510.1016/j.pharmthera.2012.07.00322796517Open DOISearch in Google Scholar
Rebillard A, Tekpli X, Meurette O, Sergent O, LeMoigne-Muller G, Vernhet L, et al. Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res 2007; 67: 7865-74. 10.1158/0008-5472.CAN-07-0353RebillardATekpliXMeuretteOSergentOLeMoigne-MullerGVernhetLCisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cellsCancer Res20076778657410.1158/0008-5472.CAN-07-035317699793Open DOISearch in Google Scholar
Bose RN, Yang WW, Evanics F. Structural perturbation of a C4 zinc-finger module by cis-diamminedichloroplatinum(II): insights into the inhibition of transcription processes by the antitumor drug. Inorganica Chim Acta 2005; 358: 2844-54. org/10.1016/j.ica.2004.06.052BoseRNYangWWEvanicsFStructural perturbation of a C4 zinc-finger module by cis-diamminedichloroplatinum(II): insights into the inhibition of transcription processes by the antitumor drugInorganica Chim Acta2005358284454org/10.1016/j.ica.2004.06.052Open DOISearch in Google Scholar
Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H. Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action. Bioconjugate Chem 2016; 27: 2132-48. 10.1021/acs.bioconjchem.6b00353HuangXHuangRGouSWangZLiaoZWangHCombretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of actionBioconjugate Chem20162721324810.1021/acs.bioconjchem.6b00353Open DOISearch in Google Scholar
Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloro-platinum(II) metabolism and ATP-dependent efflux from leukaemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993; 268: 20116-25. PMID: 8376370IshikawaTAli-OsmanFGlutathione-associated cis-diamminedichloro-platinum(II) metabolism and ATP-dependent efflux from leukaemia cells. Molecular characterization of glutathione-platinum complex and its biological significanceJ Biol Chem19932682011625PMID: 837637010.1016/S0021-9258(20)80702-9Search in Google Scholar
Hostetter AA, Osborn MF, DeRose VJ. RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae. ACS Chem Biol 2012; 7: 218-25. 10.1021/cb200279pHostetterAAOsbornMFDeRoseVJRNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiaeACS Chem Biol201272182510.1021/cb200279pOpen DOISearch in Google Scholar
Wolters DA, Stefanopoulou M, Dyson PJ, Groessl M. Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells. Metallomics 2012; 4: 1185-96. 10.1039/c2mt20070hWoltersDAStefanopoulouMDysonPJGroesslMCombination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cellsMetallomics2012411859610.1039/c2mt20070hOpen DOISearch in Google Scholar
Palermo G, Magistrato A, Riedel T, von Erlach T, Davey CA, Dyson PJ, et al. Fighting cancer with transition metal complexes: from naked DNA to protein and chromatin targeting strategies. Chem Med Chem 2016; 11: 1199-210. 10.1002/cmdc.201500478PalermoGMagistratoARiedelTvon ErlachTDaveyCADysonPJFighting cancer with transition metal complexes: from naked DNA to protein and chromatin targeting strategiesChem Med Chem201611119921010.1002/cmdc.201500478Open DOISearch in Google Scholar
Zou T, Lum CT, Lok CN, Zhang JJ, Che CM. Chemical biology of anticancer gold(III) and gold(I) complexes. Chem Soc Rev 2015; 44: 8786-801. 10.1039/c5cs00132cZouTLumCTLokCNZhangJJCheCMChemical biology of anticancer gold(III) and gold(I) complexesChem Soc Rev201544878680110.1039/c5cs00132cOpen DOISearch in Google Scholar
Molter A, Kathrein S, Kircher B, Mohr F. Anti-tumour active gold(I), palladium(II) and ruthenium(II) complexes with thio- and selenoureato ligands: a comparative study. Dalton Trans 2018; 47: 5055. 10.1039/C7DT04180BMolterAKathreinSKircherBMohrFAnti-tumour active gold(I), palladium(II) and ruthenium(II) complexes with thio- and selenoureato ligands: a comparative studyDalton Trans201847505510.1039/C7DT04180BOpen DOISearch in Google Scholar
Tshuva EY, Miller M. Coordination complexes of titanium(IV) for anticancer therapy. Met Ions Life Sci 2018; 18. 10.1515/9783110470734-014TshuvaEYMillerMCoordination complexes of titanium(IV) for anticancer therapyMet Ions Life Sci20181810.1515/9783110470734-014Open DOISearch in Google Scholar
Cini M, Bradshaw TD, Woodward S. Using titanium complexes to defeat cancer: the view from the shoulders of titans. Chem Soc Rev 2017; 4: 1040-51. 10.1039/c6cs00860gCiniMBradshawTDWoodwardSUsing titanium complexes to defeat cancer: the view from the shoulders of titansChem Soc Rev2017410405110.1039/c6cs00860gOpen DOISearch in Google Scholar
Meléndez E. Titanium complexes in cancer treatment. Crit Rev Oncol Hematol 2002; 42: 309-15. 10.1016/S1040-8428(01)00224-4MeléndezE.Titanium complexes in cancer treatmentCrit Rev Oncol Hematol2002423091510.1016/S1040-8428(01)00224-4Open DOISearch in Google Scholar
Ang DL, Gordon CP, Aldrich-Wright JR. Transition metal intercalators as anticancer agents - recent advances. Int J Mol Sci 2016; 17: 1-17. 10.3390/ijms17111818AngDLGordonCPAldrich-WrightJRTransition metal intercalators as anticancer agents - recent advancesInt J Mol Sci20161711710.3390/ijms17111818513381927809241Open DOISearch in Google Scholar
